How should a mildly equivocal overnight dexamethasone suppression test be managed in an asymptomatic patient with an adrenal adenoma?

Management of Mildly Equivocal Dexamethasone Suppression Test in Asymptomatic Patient with Adrenal Adenoma

Perform a second confirmatory test—either late-night salivary cortisol (two measurements), 24-hour urinary free cortisol (two measurements), or a 2-day low-dose dexamethasone suppression test—and refer to an endocrinologist for further evaluation. 1

Algorithmic Approach to Equivocal Results

Step 1: Define "Mildly Equivocal"

The overnight 1-mg dexamethasone suppression test yields three interpretive zones:

• Normal suppression: Post-dexamethasone cortisol <50 nmol/L (1.8 μg/dL) effectively excludes autonomous cortisol secretion 1, 2
• Equivocal zone: Post-dexamethasone cortisol 50-138 nmol/L (1.8-5.0 μg/dL) represents the gray zone requiring additional testing 2
• Clearly abnormal: Post-dexamethasone cortisol >138 nmol/L (>5.0 μg/dL) strongly suggests autonomous cortisol secretion 2, 3

Important caveat: Recent research suggests the 50 nmol/L threshold may be too low, with some studies proposing 66 nmol/L as more appropriate 4. However, current guidelines still use 50 nmol/L as the standard cutoff.

Step 2: Perform Second Test

The Endocrine Society guidelines explicitly recommend that patients with at least one abnormal test result undergo further evaluation by an endocrinologist to confirm or exclude the diagnosis 1. Choose one of these complementary tests:

• Late-night salivary cortisol (two measurements): Sensitivity and specificity approaching 90-95%; tests loss of circadian rhythm 2
• 24-hour urinary free cortisol (at least two measurements): Measures integrated cortisol production; values >4× upper limit of normal are diagnostic 2
• 2-day low-dose dexamethasone suppression test (2 mg/day for 48 hours): Alternative confirmatory test 1

Step 3: Interpret Concordance

• Two concordant abnormal results: Proceed to determine etiology of Cushing's syndrome (measure ACTH, imaging) 1
• Two concordant normal results: No further evaluation needed 1
• Discordant results: Additional testing and endocrinology follow-up required, especially if pretest probability is high (patient has adrenal incidentaloma) 1

Critical Considerations for Asymptomatic Patients

Exclude False Positives

Before proceeding with additional testing, verify:

• No exogenous glucocorticoid exposure: Obtain thorough drug history including topical, inhaled, and injected steroids 1
• No medications affecting dexamethasone metabolism: CYP3A4 inducers (phenobarbital, carbamazepine, phenytoin, rifampin) accelerate dexamethasone clearance, causing false positives 1, 5
• No medications affecting cortisol binding: Oral estrogens increase CBG, elevating total cortisol 6
• Adequate dexamethasone absorption: Consider measuring dexamethasone levels if malabsorption suspected 6
• No physiologic hypercortisolism: Exclude depression, alcoholism, severe obesity, poorly controlled diabetes 1, 6

Assess ACTH to Confirm Adrenal Origin

In patients with adrenal adenomas and equivocal dexamethasone suppression, measure ACTH levels:

• Suppressed ACTH (<2.0 pmol/L) confirms adrenal origin of autonomous cortisol secretion 2
• Post-dexamethasone ACTH <0.6 pmol/L has 75% sensitivity and 78% specificity for detecting inadequate HPA axis suppression 7

Special Consideration for Primary Aldosteronism

The 2025 Primary Aldosteronism guideline specifically recommends dexamethasone suppression testing in patients with PA and adrenal adenoma, as 5-27% of PA patients have coexisting autonomous cortisol secretion 8. This is relevant because:

• Co-secretion affects adrenal vein sampling interpretation
• Risk of postoperative glucocorticoid deficiency exists
• Increased cardiometabolic complications occur with dual hormone excess 8

Management Based on Final Classification

If Mild Autonomous Cortisol Secretion (MACS) Confirmed

MACS definition: Post-dexamethasone cortisol >50 nmol/L with suppressed ACTH, no overt Cushingoid features 8, 2

For younger patients with progressive metabolic comorbidities (hypertension, diabetes, obesity, osteoporosis) attributable to cortisol excess:

• Consider adrenalectomy after shared decision-making 9
• Minimally invasive surgery when feasible 9
• Prepare for possible postoperative adrenal insufficiency 8

For patients not managed surgically:

• Annual clinical screening for new or worsening comorbidities 9
• Monitor for progression to overt Cushing's syndrome 1

If Autonomous Cortisol Secretion Excluded

For benign adenomas <4 cm with normal hormonal evaluation:

• No further follow-up imaging or functional testing required 9

For adenomas ≥4 cm but hormonally inactive:

• Repeat imaging in 6-12 months 9
• Consider adrenalectomy if growth >5 mm/year after repeating functional workup 9

Common Pitfalls to Avoid

1. Using a single abnormal test to diagnose: Always obtain confirmatory testing before labeling a patient with autonomous cortisol secretion 1

2. Ignoring medication interactions: Antiepileptic drugs, rifampin, and St. John's wort can cause false positives 1, 5

3. Testing inappropriate populations: Do not screen asymptomatic patients without adrenal masses or multiple progressive features of hypercortisolism 1

4. Overlooking cyclic Cushing's: If clinical suspicion remains high despite normal tests, consider serial late-night salivary cortisol or UFC measurements 1

5. Failing to measure ACTH: In patients with adrenal adenomas, ACTH confirms whether cortisol excess is ACTH-independent 2

6. Not preparing for postoperative adrenal insufficiency: Patients with MACS undergoing adrenalectomy require glucocorticoid coverage and monitoring 8, 2